Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.46 |
| ▸ | DRD3 | P35462 | 4/20 | 0.46 |
| ▸ | CFTR | P13569 | 8/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496428 | 0.95 | CFTR (0.47) | DRD2DRD3CFTROPRM1OGFRL1 | |
| SCHEMBL6280446 | 0.91 | CFTR (0.47) | CFTROPRM1OGFRL1CHRNB2CHRNB4 | |
| SCHEMBL6280948 | 0.90 | CFTR (0.43) | DRD2DRD3CFTROPRM1OGFRL1 | |
| SCHEMBL6278024 | 0.90 | CFTR (0.44) | DRD2DRD3CFTROPRM1OGFRL1 | |
| SCHEMBL6280942 | 0.89 | CFTR (0.43) | DRD2DRD3CFTROPRM1OGFRL1 | |
| SCHEMBL6496683 | 0.89 | CFTR (0.46) | DRD2DRD3CFTROPRM1OGFRL1 | |
| SCHEMBL6282975 | 0.88 | CFTR (0.45) | CFTROPRM1OGFRL1 | |
| SCHEMBL6280476 | 0.88 | CFTR (0.47) | DRD2DRD3CFTRCHRNB2CHRNB4 | |
| SCHEMBL6279842 | 0.86 | CFTR (0.47) | DRD2DRD3CFTRCHRNB2CHRNB4 | |
| SCHEMBL6283290 | 0.86 | CFTR (0.52) | CFTROPRM1OGFRL1BAZ2BMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | BIOVITRUM AB (SE) | 2005-12-29 | — | — | US | claimed |
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | BIOVITRUM AB (SE) | 2005-12-29 | — | — | US | disclosed |
| WO-2005048916-A2 | TETRAHYDROSPIRO-BETA-CARBOLINE-1,3 '-PYRROLIDINE DERIVATIVES AND THEIR USE IN GHSR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288316-A1 | Beta-carbolines as growth hormone secretagogue receptor (GHSR) antagonists | GHSR, GHRHR, PRLHR | DRD2 175/4885DRD3 336/4885CFTR 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.